The requested information is provided in Portable Document Format (PDF). To view and print this document you'll need to install a copy of the free Adobe® Acrobat® Reader®. If you already have Adobe Acrobat Reader installed click "VIEW PDF" below. If you need the Acrobat Reader you can download it from the Adobe Acrobat Reader Download page.
Welcome to the SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Deforolimus) clinical trial Web site. SUCCEED is a multinational, Phase 3 trial investigating the efficacy and safety of oral deforolimus (AP23573, MK-8669) when administered as maintenance therapy to patients with metastatic soft-tissue or bone sarcomas who have had a favorable outcome to chemotherapy.
Deforolimus is an investigational agent and has not been approved by the US Food and Drug Administration (FDA) or regulatory agencies in any other country.
ARIAD Pharmaceuticals, Inc. and Merck & Co., Inc. have a global collaboration to jointly investigate deforolimus for the treatment of cancer.
The SUCCEED trial Web site is intended for US residents only.
Click here to find out whether you or your loved one may be eligible for this clinical trial.
The SUCCEED trial Web site is intended for US residents only. It is intended for Investigators, Healthcare Professionals, and Patients and Caregivers. The use of deforolimus (AP23573, MK-8669) is limited to investigational trials. There is no guarantee that its use will be approved by the US Food and Drug Administration.
This site is brought to you by ARIAD Pharmaceuticals, Inc. and Merck & Co., Inc.
© 2008 ARIAD Pharmaceuticals, Inc.
Copyright © 2008 Merck & Co., Inc. All rights reserved.
